Early and proactive engagement with developers is an “absolute imperative” and the UK’s swift approval of a COVID-19 vaccine should be a lesson in how the UK approaches the future development of vaccines and medicines.
Flexibility And Agility Key To Speedy UK COVID Vaccine Approval
MRHA Head Insists No Compromises Were Made In Review Of Pfizer/BioNTech Vaccine
The flexibility and agility of parallel teams of scientists and clinicians who worked around the clock were key to speedy UK approval of the COVID-19 vaccine, according to UK agency head June Raine. Canada has also just announced that it has approved the Pfizer/BioNTech vaccine.
More from Archive
More from Pink Sheet
• By
During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.
• By
US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.
• By
US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.